Dermata Therapeutics Inc. Appoints Baker Tilly as New Certifying Accountant Following Merger

Reuters
06 Jun
<a href="https://laohu8.com/S/DRMA">Dermata Therapeutics Inc</a>. Appoints Baker Tilly as New Certifying Accountant Following Merger

Dermata Therapeutics Inc. has announced a change in its certifying accountants following the merger of Moss Adams LLP with Baker Tilly US, LLP, effective June 3, 2025. The audit committee of Dermata's Board of Directors has approved the appointment of Baker Tilly as the company's new independent registered public accounting firm, succeeding Moss Adams. The transition comes without any disagreements or reportable events regarding accounting principles or practices during the years 2023 and 2024, as well as the interim period through June 3, 2025. Moss Adams' audit reports for these years did not contain adverse opinions but included an explanatory paragraph about a going concern uncertainty.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-013823), on June 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10